Published in J Clin Invest on March 01, 1986
Biochemical markers of bone turnover: potential use in the investigation and management of postmenopausal osteoporosis. Osteoporos Int (2008) 1.50
Gamma-carboxyglutamate-containing proteins and the vitamin K-dependent carboxylase. Biochem J (1990) 1.45
Hypercalcemia in malignancy. West J Med (1990) 1.24
New developments in biochemical markers for osteoporosis. Calcif Tissue Int (1996) 1.08
Metastatic breast cancer cells suppress osteoblast adhesion and differentiation. Clin Exp Metastasis (2004) 1.03
Biochemical markers of bone turnover for the clinical investigation of osteoporosis. Osteoporos Int (1993) 1.02
Bone mineral density and bone turnover markers in children with chronic renal failure. Pediatr Nephrol (2004) 0.87
Selenium modifies the osteoblast inflammatory stress response to bone metastatic breast cancer. Carcinogenesis (2009) 0.85
Effects of active vitamin D3 and parathyroid hormone on the serum osteocalcin in idiopathic hypoparathyroidism and pseudohypoparathyroidism. J Clin Invest (1988) 0.81
Potential utility of high preoperative levels of serum type I collagen markers in postmenopausal women with primary hyperparathyroidism with respect to their short-term variations after parathyroidectomy. J Bone Miner Metab (2009) 0.78
Bone Turnover Markers in the Diagnosis and Monitoring of Metabolic Bone Disease. Clin Chem (2016) 0.75
Modifications of a specific assay for hydroxyproline in urine. Anal Biochem (1967) 5.48
Primary hyperparathyroidism. Incidence, morbidity, and potential economic impact in a community. N Engl J Med (1980) 4.96
Interpretation of serum calcium in patients with abnormal serum proteins. Br Med J (1973) 4.13
Direct identification of the calcium-binding amino acid, gamma-carboxyglutamate, in mineralized tissue. Proc Natl Acad Sci U S A (1975) 3.46
Biochemical evaluation of patients with cancer-associated hypercalcemia: evidence for humoral and nonhumoral groups. N Engl J Med (1980) 3.15
Characterization of a gamma-carboxyglutamic acid-containing protein from bone. Proc Natl Acad Sci U S A (1976) 3.15
Serum bone Gla-protein: a specific marker for bone formation in postmenopausal osteoporosis. Lancet (1984) 2.85
New biochemical marker for bone metabolism. Measurement by radioimmunoassay of bone GLA protein in the plasma of normal subjects and patients with bone disease. J Clin Invest (1980) 2.48
The hypercalcemia of cancer. Clinical implications and pathogenic mechanisms. N Engl J Med (1984) 2.33
Primary hyperparathyroidism: changes in the pattern of clinical presentation. Lancet (1980) 2.19
Origin of the vitamin K-dependent bone protein found in plasma and its clearance by kidney and bone. J Biol Chem (1981) 1.99
Radioimmunoassay for the vitamin K-dependent protein of bone and its discovery in plasma. Proc Natl Acad Sci U S A (1980) 1.73
Increase in serum bone gamma-carboxyglutamic acid protein with aging in women. Implications for the mechanism of age-related bone loss. J Clin Invest (1983) 1.69
Quantitative bone histomorphometry in humoral hypercalcemia of malignancy: uncoupling of bone cell activity. J Clin Endocrinol Metab (1982) 1.68
Physiological senile involution and pathological rarefaction of bone. Quantitative and comparative histological data. Clin Endocrinol Metab (1973) 1.66
Secretion of the vitamin K-dependent protein of bone by rat osteosarcoma cells. Evidence for an intracellular precursor. J Biol Chem (1980) 1.37
Mechanisms of hypercalcemia in malignancy. Cancer (1978) 1.13
Effect of renal function on plasma levels of bone Gla-protein. J Clin Endocrinol Metab (1983) 1.11
Relative contribution of humoral and metastatic factors to the pathogenesis of hypercalcaemia in malignancy. Br Med J (Clin Res Ed) (1984) 1.05
Clinical evaluation of bone turnover by serum osteocalcin measurements in a hospital setting. J Clin Endocrinol Metab (1984) 1.03
Assessment of bone turnover in postmenopausal osteoporosis by measurement of serum bone Gla-protein. J Lab Clin Med (1983) 1.02
Changes in plasma bone GLA protein during treatment of bone disease. Calcif Tissue Int (1982) 0.99
Urinary gamma-carboxyglutamic acid and serum osteocalcin as bone markers: studies in osteoporosis and Paget's disease. J Clin Endocrinol Metab (1983) 0.97
A tetracycline-based histomorphometric evaluation of bone resorption and bone turnover in hyperthyroidism and hyperparathyroidism. Acta Med Scand (1978) 0.96
Bone histomorphometry in Paget's disease. Quantitative and dynamic analysis of pagetic and nonpagetic bone tissue. Arthritis Rheum (1980) 0.93
SKELETAL ALTERATIONS IN HYPERPARATHYROIDISM: DETERMINATION OF BONE FORMATION, RESORPTION AND MORPHOLOGIC CHANGES BY MICRORADIOGRAPHY. J Clin Endocrinol Metab (1965) 0.92
Plasma levels of bone Gla-protein reflect bone formation in patients on chronic maintenance dialysis. Kidney Int (1984) 0.91
Quantitative bone histology in the hypercalcemia of malignant disease. J Clin Endocrinol Metab (1982) 0.90
Quantitative histology of bone in hyperparathyroidism. Its relation to clinical features, x-ray, and biochemistry. Q J Med (1971) 0.86
Abnormal bone and parathyroid histology in carcinoma patients with pseudohyperparathyroidism. Cancer (1982) 0.80
Effects of parathyroid hormone on remodeling of iliac trabecular bone packets in patients with primary hyperparathyroidism. Clin Orthop Relat Res (1982) 0.78
Thickness of lamellae in normal human iliac trabecular bone. Metab Bone Dis Relat Res (1983) 0.77
Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res (1987) 24.27
Vitamin D3 and calcium to prevent hip fractures in the elderly women. N Engl J Med (1992) 9.86
Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med (2001) 9.57
Prevalence of vitamin D insufficiency in an adult normal population. Osteoporos Int (1997) 5.82
Body mass index as a predictor of fracture risk: a meta-analysis. Osteoporos Int (2005) 5.54
European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int (2008) 5.27
Dietary supplementation in elderly patients with fractured neck of the femur. Lancet (1990) 4.47
Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med (1998) 4.38
Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab (2005) 3.67
Osteoporosis and the replacement of cell populations of the marrow by adipose tissue. A quantitative study of 84 iliac bone biopsies. Clin Orthop Relat Res (1971) 3.58
Do we need to change the WHO definition of osteoporosis? Osteoporos Int (2000) 3.35
Fall-related factors and risk of hip fracture: the EPIDOS prospective study. Lancet (1996) 3.18
An international comparison of serum 25-hydroxyvitamin D measurements. Osteoporos Int (1999) 3.07
Serum bone Gla-protein: a specific marker for bone formation in postmenopausal osteoporosis. Lancet (1984) 2.85
Ultrasonographic heel measurements to predict hip fracture in elderly women: the EPIDOS prospective study. Lancet (1996) 2.83
Combined calcium and vitamin D3 supplementation in elderly women: confirmation of reversal of secondary hyperparathyroidism and hip fracture risk: the Decalyos II study. Osteoporos Int (2002) 2.82
Current use of bisphosphonates in oncology. International Bone and Cancer Study Group. J Clin Oncol (1998) 2.73
Interim report and recommendations of the World Health Organization Task-Force for Osteoporosis. Osteoporos Int (1999) 2.70
Osteoblast and chondroblast differentiation. Bone (1995) 2.65
Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study. J Bone Miner Res (1996) 2.61
Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women. BMJ (1994) 2.61
Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J Bone Miner Res (1996) 2.59
The collagenolytic activity of cathepsin K is unique among mammalian proteinases. J Biol Chem (1998) 2.48
Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab (1994) 2.39
Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study. Osteoporos Int (2006) 2.34
Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study Group. J Clin Endocrinol Metab (2000) 2.34
Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest (1997) 2.33
Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: a multicentre trial. Br Med J (1980) 2.29
Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study. J Bone Miner Res (2000) 2.24
Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone (2000) 2.24
The role of collagen in bone strength. Osteoporos Int (2005) 2.19
Cross sectional evaluation of biochemical markers of bone, cartilage, and synovial tissue metabolism in patients with knee osteoarthritis: relations with disease activity and joint damage. Ann Rheum Dis (2001) 2.18
Insights into material and structural basis of bone fragility from diseases associated with fractures: how determinants of the biomechanical properties of bone are compromised by disease. Endocr Rev (2006) 2.08
Undercarboxylated osteocalcin measured with a specific immunoassay predicts hip fracture in elderly women: the EPIDOS Study. J Clin Endocrinol Metab (1997) 2.04
Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res (2003) 1.96
Molecular basis and clinical use of biochemical markers of bone, cartilage, and synovium in joint diseases. Arthritis Rheum (2000) 1.85
Mean wall thickness of trabecular bone packets in the human iliac crest: changes with age. Calcif Tissue Res (1978) 1.83
Measurement of bone mineral content of the lumbar spine by dual energy x-ray absorptiometry in normal children: correlations with growth parameters. J Clin Endocrinol Metab (1990) 1.83
Quantitative histological data on disuse osteoporosis: comparison with biological data. Calcif Tissue Res (1974) 1.83
Serum undercarboxylated osteocalcin is a marker of the risk of hip fracture: a three year follow-up study. Bone (1996) 1.80
Serum undercarboxylated osteocalcin is a marker of the risk of hip fracture in elderly women. J Clin Invest (1993) 1.78
Exercise before puberty may confer residual benefits in bone density in adulthood: studies in active prepubertal and retired female gymnasts. J Bone Miner Res (1998) 1.77
Ibandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient data. Osteoporos Int (2008) 1.76
The effect of vitamin D supplementation on vitamin D status and parathyroid function in elderly subjects. J Clin Endocrinol Metab (1988) 1.71
Long-term effects of intravenous pamidronate in fibrous dysplasia of bone. Lancet (1994) 1.71
How hip and whole-body bone mineral density predict hip fracture in elderly women: the EPIDOS Prospective Study. Osteoporos Int (1998) 1.70
Increase in serum bone gamma-carboxyglutamic acid protein with aging in women. Implications for the mechanism of age-related bone loss. J Clin Invest (1983) 1.69
The type I collagen fragments ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradation. J Bone Miner Res (2003) 1.68
Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis (2005) 1.66
Physiological senile involution and pathological rarefaction of bone. Quantitative and comparative histological data. Clin Endocrinol Metab (1973) 1.66
Urinary excretion of pyridinium crosslinks: a new marker of bone resorption in metabolic bone disease. Bone Miner (1990) 1.62
Comparison of trabecular bone microarchitecture and remodeling in glucocorticoid-induced and postmenopausal osteoporosis. J Bone Miner Res (2001) 1.62
The deleterious effects of low-dose corticosteroids on bone density in patients with polymyalgia rheumatica. Br J Rheumatol (1998) 1.59
Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum (2001) 1.58
Alendronate and estrogen effects in postmenopausal women with low bone mineral density. Alendronate/Estrogen Study Group. J Clin Endocrinol Metab (2000) 1.58
Glucocorticoid-induced inhibition of osteoblastic bone formation in ewes: a biochemical and histomorphometric study. Osteoporos Int (1993) 1.58
Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis--a 2-year randomized placebo controlled trial. J Clin Endocrinol Metab (2002) 1.57
Markers of bone turnover for the management of patients with bone metastases from prostate cancer. Br J Cancer (2000) 1.56
Incidence of limb fracture across Europe: results from the European Prospective Osteoporosis Study (EPOS). Osteoporos Int (2002) 1.56
The T3R alpha gene encoding a thyroid hormone receptor is essential for post-natal development and thyroid hormone production. EMBO J (1997) 1.54
Independent predictors of all osteoporosis-related fractures in healthy postmenopausal women: the OFELY study. Bone (2003) 1.54
The degree of mineralization is a determinant of bone strength: a study on human calcanei. Bone (2004) 1.54
Genetic analysis reveals different functions for the products of the thyroid hormone receptor alpha locus. Mol Cell Biol (2001) 1.54
Healthy elderly French women living at home have secondary hyperparathyroidism and high bone turnover in winter. EPIDOS Study Group. J Clin Endocrinol Metab (1996) 1.53
Risk-benefit ratio of sodium fluoride treatment in primary vertebral osteoporosis. Lancet (1988) 1.50
Biochemical markers of bone turnover: potential use in the investigation and management of postmenopausal osteoporosis. Osteoporos Int (2008) 1.50
Prevention and treatment of osteoporosis. Aging (Milano) (1995) 1.50
Fluoride and vertebral fractures. Lancet (1990) 1.48
Strontium distribution and interactions with bone mineral in monkey iliac bone after strontium salt (S 12911) administration. J Bone Miner Res (1996) 1.48
Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling. Am J Med (1995) 1.48
Serum and synovial fluid osteocalcin (bone gla protein) levels in joint disease. Br J Rheumatol (1989) 1.48
Prevention of early postmenopausal bone loss with cyclical etidronate therapy (a double-blind, placebo-controlled study and 1-year follow-up) J Clin Endocrinol Metab (1997) 1.48
Bisphosphonates alter trabecular bone collagen cross-linking and isomerization in beagle dog vertebra. Osteoporos Int (2007) 1.47
Calcium and vitamin D supplements: effects on calcium metabolism in elderly people. Am J Clin Nutr (1987) 1.46